imidazol-1-ylacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

imidazol-1-ylacetic acid : An imidazolyl carboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by an imidazol-1-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	656129
CHEMBL ID	297390
CHEBI ID	70801
SCHEMBL ID	77978

Synonyms (65)

Synonym
HMS1684C18
AC-20545
BB 0240486
MLS000074022
imidazol-1-yl-acetic acid
EC-000.1971
22884-10-2
smr000013538
STK260846
1h-imidazol-1-ylacetic acid ,
1-imidazolylacetic acid
I0670
1-(carboxymethyl)imidazole
2-(1-imidazolyl)acetic acid
1-imidazoleacetic acid
chebi:70801 ,
CHEMBL297390 ,
2-(3h-imidazol-4-yl)acetic acid
qafbdrsxxhexgb-uhfffaoysa-
inchi=1/c5h6n2o2/c8-5(9)3-7-2-1-6-4-7/h1-2,4h,3h2,(h,8,9)
2-imidazol-1-ylacetic acid
AKOS000137844
A24846
BBL001468
2-(1h-imidazol-1-yl)acetic acid
1h-imidazole-1-acetic acid
imidazol-1-yl acetic acid
HMS2349E08
FT-0670304
BP-11530
FT-0638263
imidazole-1-acetic acid
whc1j1g932 ,
unii-whc1j1g932
AM20090233
(1-imidazolyl)acetic acid
AB09874
AB00419076-07
imidazol-1-ylacetic acid
2-(imidazol-1-yl)acetic acid
zoledronic acid monohydrate impurity d [ep impurity]
SCHEMBL77978
AB00419076-09
[1h-imidazol-1-yl]acetic acid
2-(n-imidazolyl)acetic acid
QAFBDRSXXHEXGB-UHFFFAOYSA-N
1h-imidazole-1-ylacetic acid
(1h-imidazol-1-yl)acetic acid
SY003214
mfcd01721800
RS-0402
CS-W011164
DTXSID20177425
F8881-7832
J-521520
1h-imidazol-1-ylacetic acid, aldrichcpr
bdbm50026406
Z57396183
J-014887
Q27139105
2-(1h-imidazol-1-yl)aceticacid
imidazole-1-yl-acetic acid
HY-W010448
imidazol-1-yl-essigsaeure, 1h-imidazole-1-acetic acid, imidazole-1-acetic acid
EN300-57904

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

Class	Description
imidazolyl carboxylic acid	Any member of the class of imidazoles in which the imidazole ring is substituted by one (or more) carboxy group(s).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	39.8107	0.0112	12.4002	100.0000	AID1030
bromodomain adjacent to zinc finger domain 2B	Homo sapiens (human)	Potency	100.0000	0.7079	36.9043	89.1251	AID504333
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	89.1251	0.0355	20.9770	89.1251	AID504332
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	7.3078	5.8048	36.1306	65.1308	AID540253
snurportin-1	Homo sapiens (human)	Potency	7.3078	5.8048	36.1306	65.1308	AID540253
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	7.3078	5.8048	16.9962	25.9290	AID540253
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sodium- and chloride-dependent GABA transporter 2	Mus musculus (house mouse)	IC50 (µMol)	199.5260	1.4125	5.2683	8.1283	AID595474
Sodium- and chloride-dependent GABA transporter 3	Mus musculus (house mouse)	IC50 (µMol)	42.6579	1.5488	3.6761	8.1283	AID595475
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay ID	Title	Year	Journal	Article
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID595477	Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595476	Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595509	Selectivity ratio of pIC50 for mouse GAT3 topIC50 for mouse GAT1	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595475	Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595474	Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595482	Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT2	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595483	Selectivity ratio of pIC50 for mouse GAT3 to pIC50 for mouse GAT4	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (11.11)	29.6817
2010's	6 (66.67)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.10 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.40 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.10)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.	2.06	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule
5-aminovaleric acid 5-aminovaleric acid: from red fox anal secretion; RN given refers to parent cpd. 5-aminopentanoic acid : A delta-amino acid comprising pentanoic acid with an amino substituent at C-5; a methylene homologue of gamma-aminobutyric acid (GABA) that is a weak GABA agonist.	2.06	1	amino acid zwitterion; delta-amino acid; omega-amino fatty acid	human metabolite
beta-alanine [no description available]	2.06	1	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	2.06	1	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
glycine [no description available]	2.06	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
omega-aminoenantic acid [no description available]	2.06	1	medium-chain fatty acid
5-imidazolepropionic acid 5-imidazolepropionic acid: competitive inhibitor of urocanase reaction which catalyzes conversion of urocanate into imidazolone propionate; structure. dihydrourocanic acid : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 3 has been replaced by an imidazol-4-yl group.	2.06	1	imidazoles; monocarboxylic acid
imidazoleacetic acid imidazoleacetic acid: RN given refers to cpd without specific location of acetic acid attachment identified; structure. imidazol-5-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-5-yl group.. imidazol-4-ylacetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by an imidazol-4-yl group.	2.06	1	imidazoles; monocarboxylic acid	metabolite; mouse metabolite
5-benzimidazolecarboxylic acid 5-benzimidazolecarboxylic acid: structure in first source	2.06	1
urocanic acid Urocanic Acid: 4-Imidazoleacrylic acid.. urocanic acid : An alpha,beta-unsaturated monocarboxylic acid that is prop-2-enoic acid substituted by a 1H-imidazol-4-yl group at position 3. It is a metabolite of hidtidine.. trans-urocanic acid : A urocanic acid in which the double bond of the carboxyethene moiety has E configuration.	2.06	1	urocanic acid	human metabolite
3-(1H-imidazol-1-yl)propanoic acid [no description available]	2.06	1	imidazolyl carboxylic acid	human urinary metabolite
snap 5114 [no description available]	2.06	1

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1

chemdatabank.com